{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:50:45Z","timestamp":1789012245173,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00277-020-04227-8","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T13:44:15Z","timestamp":1598881455000},"page":"587-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"100","author":[{"given":"Ramona","family":"Wullenkord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wethmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Albring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,22]]},"reference":[{"issue":"1","key":"4227_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 119(1):34\u201343. https:\/\/doi.org\/10.1182\/blood-2011-04-347872","journal-title":"Blood"},{"issue":"1","key":"4227_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","volume":"2016","author":"N Gokbuget","year":"2016","unstructured":"Gokbuget N (2016) Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016(1):573\u2013579. https:\/\/doi.org\/10.1182\/asheducation-2016.1.573","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4227_CR3","doi-asserted-by":"publisher","unstructured":"Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S (2018) New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol JCO2017773648. https:\/\/doi.org\/10.1200\/JCO.2017.77.3648","DOI":"10.1200\/JCO.2017.77.3648"},{"issue":"8","key":"4227_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O\u2019Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"issue":"8","key":"4227_CR5","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/cncr.31249","volume":"124","author":"EJ Jabbour","year":"2018","unstructured":"Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gokbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM (2018) Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 124(8):1722\u20131732. https:\/\/doi.org\/10.1002\/cncr.31249","journal-title":"Cancer"},{"issue":"9","key":"4227_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"14","key":"4227_CR7","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/cncr.30031","volume":"122","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, Gokbuget N, Zugmaier G, Benjamin JE, Zhang A, Jia C, Topp MS (2016) Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer 122(14):2178\u20132185. https:\/\/doi.org\/10.1002\/cncr.30031","journal-title":"Cancer"},{"issue":"26","key":"4227_CR8","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127(26):3312\u20133320. https:\/\/doi.org\/10.1182\/blood-2016-02-629063","journal-title":"Blood"},{"issue":"5","key":"4227_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"issue":"1","key":"4227_CR10","doi-asserted-by":"publisher","first-page":"IJH02","DOI":"10.2217\/ijh-2017-0023","volume":"7","author":"Y Sawalha","year":"2018","unstructured":"Sawalha Y, Advani AS (2018) Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol 7(1):IJH02. https:\/\/doi.org\/10.2217\/ijh-2017-0023","journal-title":"Int J Hematol Oncol"},{"key":"4227_CR11","doi-asserted-by":"publisher","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol JCO1902104. https:\/\/doi.org\/10.1200\/JCO.19.02104","DOI":"10.1200\/JCO.19.02104"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04227-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T23:08:46Z","timestamp":1629587326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04227-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,22]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04227-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,22]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MS holds a consulting or advisory role at MSD, Amgen, and Pfizer; and received honoraria from Jazz Pharmaceuticals, Amgen, Novartis, and Pfizer; and research funding from Pfizer. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"n.a. (no clinical study).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed written consent of the patient for all therapies and research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed written consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}